Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSIDE: Bioavailability of Disulfiram and Metformin in Glioblastoma
NCT03151772Phase 1Terminated
- Sponsor
- Sahlgrenska University Hospital
- Start
- Jan 2018
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of disulfiram and metformin in glioblastoma (GBM) (2 arms), sponsored by Sahlgrenska University Hospital. Primary endpoints: Bioavailability of Disulfiram and Bioavailability of Metformin. Started Jan 2018; status: terminated.
02
Drugs
disulfirammetformin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03151772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03151772.